标题:Rosiglitazone attenuates myocardial remodeling in spontaneously hypertensive rats
作者:Ti, Yun; Hao, Ming-Xiu; Li, Chuan-Bao; Wang, Zhi-Hao; Hou, Xiao-Yang; Zhao, Xue-Qiang; Liu, Jun-Ni; Zhang, Wei; Zhang, Yun; Bu, Pei- 更多
作者机构:[Ti, Yun; Hao, Ming-Xiu; Li, Chuan-Bao; Wang, Zhi-Hao; Hou, Xiao-Yang; Zhao, Xue-Qiang; Liu, Jun-Ni; Zhang, Wei; Zhang, Yun; Bu, Pei-Li] Shandong Univ 更多
通讯作者:Bu, PL
通讯作者地址:[Bu, PL]Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, 107 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R 更多
来源:HYPERTENSION RESEARCH
出版年:2011
卷:34
期:3
页码:354-360
DOI:10.1038/hr.2010.242
关键词:myocardial remodeling; peroxisome proliferator-activated receptor;; rosiglitazone
摘要:Rosiglitazone, an important peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, improves left ventricular (LV) hypertrophy in diet-induced hypercholesterolemic rats. However, the effects and underlying mechanisms of rosiglitazone on myocardial remodeling in spontaneous hypertension rats (SHRs) are unclear. Twenty male 8-week-old SHRs were randomly divided into two groups: one treated with oral saline (n=10) and the other treated with rosiglitazone (5 mg kg(-1) day(-1), n=10). Ten age-matched Wistar-Kyoto rats were selected as a normal control group. Echocardiography, immunohistochemistry, real-time reverse transcriptase-PCR and western blot analysis were performed to assess the effects of rosiglitazone. After 16 weeks of treatment, LV hypertrophy was significantly attenuated by rosiglitazone (LV weight/body weight, 2.35 +/- 0.11 vs. 2.56 +/- 0.14 mg g(-1)). According to the echocardiography results, thickening of the LV wall was reduced, and mid-wall fractional shortening was improved by rosiglitazone. Similarly, the excessive collagen deposition and upregulation of collagen I and collagen III seen in SHRs receiving saline were significantly attenuated in SHRs receiving rosiglitazone. In addition, rosiglitazone treatment increased the activity of matrix metalloproteinase-9 (MMP-9) and normalized the MMP-9/tissue inhibitor of metalloproteinase-1 ratio. Furthermore, activator protein-1 (AP-1) activation and nuclear factor-kappa B (NF-kappa B) expression were suppressed in the rosiglitazone-treated group. These results demonstrate that the PPAR-gamma agonist rosiglitazone had beneficial effects on myocardial remodeling in SHRs by way of decreasing AP-1 activation and NF-kappa B expression, which may help in further inhibiting transcription of the downstream genes involved in the pathogenesis of myocardial remodeling induced by hypertension. Hypertension Research (2011) 34, 354-360; doi:10.1038/hr.2010.242; published online 20 January 2011
收录类别:SCOPUS;SCIE
WOS核心被引频次:3
Scopus被引频次:3
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952377881&doi=10.1038%2fhr.2010.242&partnerID=40&md5=f3b22586e73c73f54619e5d6e3dde4b9
TOP